AU1580395A - Microgranules of 5-nitro imidazole derivatives - Google Patents

Microgranules of 5-nitro imidazole derivatives

Info

Publication number
AU1580395A
AU1580395A AU15803/95A AU1580395A AU1580395A AU 1580395 A AU1580395 A AU 1580395A AU 15803/95 A AU15803/95 A AU 15803/95A AU 1580395 A AU1580395 A AU 1580395A AU 1580395 A AU1580395 A AU 1580395A
Authority
AU
Australia
Prior art keywords
microgranules
imidazole derivatives
medicinal
nitro imidazole
hand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU15803/95A
Other versions
AU705570B2 (en
Inventor
Patrice Debregeas
Gerard Leduc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethypharm SAS
Original Assignee
Ethypharm SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9400394A external-priority patent/FR2715067B1/en
Application filed by Ethypharm SAS filed Critical Ethypharm SAS
Publication of AU1580395A publication Critical patent/AU1580395A/en
Application granted granted Critical
Publication of AU705570B2 publication Critical patent/AU705570B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Medicinal form contains a combination of microgranules of derivatives 5-nitroimidasole, consisting, on the one hand, of gastro-resistant microgranules and, on the other hand, of microgranules with a prolonged release of a medicinal agent. Gastroresistant microgranules are intended to guarantee the efficiency of the medicinal form of the present invention, primarily, in the upper part of gastrointestinal tract, while the microgranules with a prolonged medicinal agent release are operate mainly in the lower part of gastrointestinal tract.
AU15803/95A 1994-01-14 1995-01-12 Microgranules of 5-nitro imidazole derivatives Ceased AU705570B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9400394A FR2715067B1 (en) 1994-01-14 1994-01-14 New dosage form of 5-nitro-imidazole derivatives effective for the treatment of parasitic infections and infections of the entire gastrointestinal tract.
FR94/00394 1994-01-14
PCT/FR1995/000039 WO1995019168A1 (en) 1994-01-14 1995-01-12 Microgranules of 5-nitro imidazole derivatives

Publications (2)

Publication Number Publication Date
AU1580395A true AU1580395A (en) 1995-08-01
AU705570B2 AU705570B2 (en) 1999-05-27

Family

ID=9459066

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15803/95A Ceased AU705570B2 (en) 1994-01-14 1995-01-12 Microgranules of 5-nitro imidazole derivatives

Country Status (19)

Country Link
JP (1) JPH09507499A (en)
KR (1) KR100320140B1 (en)
CN (1) CN1088357C (en)
AT (1) ATE187068T1 (en)
AU (1) AU705570B2 (en)
BR (1) BR9506507A (en)
CZ (1) CZ286080B6 (en)
DE (1) DE69513632T2 (en)
DK (1) DK0739201T3 (en)
ES (1) ES2139883T3 (en)
MA (1) MA23429A1 (en)
MX (1) MX9602772A (en)
NZ (1) NZ279238A (en)
OA (1) OA10583A (en)
PL (1) PL178424B1 (en)
PT (1) PT739201E (en)
RU (1) RU2152212C1 (en)
SK (1) SK282066B6 (en)
UA (1) UA28031C2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10849884B2 (en) 2014-09-05 2020-12-01 Lupin Inc. Secnidazole for use in the treatment of bacterial vaginosis

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4331930B2 (en) * 2001-10-17 2009-09-16 武田薬品工業株式会社 High content granules of acid labile drugs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256684A (en) * 1985-06-13 1993-10-26 The Procter & Gamble Company Methods and compositions for the treatment of gastrointestinal disorders
DE3822095A1 (en) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab NEW MEDICAMENT FORMULATION AND METHOD FOR THE PRODUCTION THEREOF
DE69131574T2 (en) * 1990-05-14 2000-05-04 Gary R. Jernberg SURGICAL IMPLANT AND METHOD FOR EMBEDDING CHEMOTHERAPEUTICS

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10849884B2 (en) 2014-09-05 2020-12-01 Lupin Inc. Secnidazole for use in the treatment of bacterial vaginosis
US10857133B2 (en) 2014-09-05 2020-12-08 Lupin Inc. Secnidazole for use in the treatment of bacterial vaginosis
US11000508B2 (en) 2014-09-05 2021-05-11 Lupin Inc. Secnidazole for use in the treatment of trichomoniasis
US11000507B2 (en) 2014-09-05 2021-05-11 Lupin Inc. Secnidazole for use in the treatment of bacterial vaginosis
US11020377B2 (en) 2014-09-05 2021-06-01 Lupin Inc. Secnidazole for use in the treatment of bacterial vaginosis
US11324721B2 (en) 2014-09-05 2022-05-10 Lupin Inc. Secnidazole for use in the treatment of trichomoniasis
US11602522B2 (en) 2014-09-05 2023-03-14 Lupin Inc. Secnidazole for use in the treatment of sexually transmitted infection
US11684607B2 (en) 2014-09-05 2023-06-27 Lupin, Inc. Secnidazole for use in the treatment of bacterial vaginosis

Also Published As

Publication number Publication date
ES2139883T3 (en) 2000-02-16
MX9602772A (en) 1997-05-31
CZ205596A3 (en) 1996-10-16
KR100320140B1 (en) 2002-07-02
BR9506507A (en) 1997-09-09
CN1088357C (en) 2002-07-31
DE69513632T2 (en) 2000-04-06
NZ279238A (en) 1998-03-25
JPH09507499A (en) 1997-07-29
OA10583A (en) 2002-07-10
SK282066B6 (en) 2001-10-08
RU2152212C1 (en) 2000-07-10
SK91496A3 (en) 1996-12-04
PL315530A1 (en) 1996-11-12
PT739201E (en) 2000-05-31
DE69513632D1 (en) 2000-01-05
AU705570B2 (en) 1999-05-27
MA23429A1 (en) 1995-10-01
DK0739201T3 (en) 2000-05-01
UA28031C2 (en) 2000-10-16
CN1138826A (en) 1996-12-25
ATE187068T1 (en) 1999-12-15
PL178424B1 (en) 2000-04-28
CZ286080B6 (en) 2000-01-12

Similar Documents

Publication Publication Date Title
CA2216437A1 (en) Pharmaceutical composition containing selected lanthanum carbonate hydrates
EP2261200A3 (en) Modified forms of pharmacacologically active agents and uses therefor
AU763094C (en) Benzimidazoles, production thereof and use thereof as medicaments
AU3119195A (en) Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy
WO2000012112A3 (en) Treatment of lesions with xanthine oxidoreductase
AU1392900A (en) 2,5-diazabicyclo(2.2.1)heptane derivatives, their preparation and therapeutic uses
USD412224S (en) Portable pet ramp
EP1003526A4 (en) Covalently linked n,o-carboxymethylchitosan and uses thereof
AU7459600A (en) Smooth muscle cell promoter and uses thereof
AU8918998A (en) Non-immunosuppressive cyclosporins and their use in the prevention and treatmentof hiv infection
USD395140S (en) Furcal lampholder support for use on track
AU2091100A (en) The optical quantum medical technology and the instrument thereof
AU2841801A (en) Triazolotriazinones and the use thereof
WO2003045429A3 (en) Anti-t cell immunotoxin fusion protein and its therapeutic use
WO1998053850A3 (en) Compositions and means for the treatment of burns and other cutaneous traumas
AU2011501A (en) Benzimidazoles, production thereof and the use thereof as antithrombotic
AU4789099A (en) Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents
WO1999021574A3 (en) Enhancement of morphogen activity
AU1580395A (en) Microgranules of 5-nitro imidazole derivatives
AU3853097A (en) Benzimidazole derivatives, preparation thereof, and therapeutical uses thereof
WO1999020259A3 (en) Compositions containing thiamphenicol and diclofenac
HK1045514A1 (en) Optically pure camptothecin analogues and composition and use thereof.
USD428446S (en) Game apparatus
WO1999064065A3 (en) Tumour therapy and imaging
WO2000017366A3 (en) Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug